View Older Stories View More Recent Stories

May 21, 2018 07:01AM Fibrocell Science (FCSC) Announces Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy
May 21, 2018 07:00AM Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 21, 2018 07:00AM Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 16, 2018 04:05PM Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
May 14, 2018 08:00AM Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
May 10, 2018 04:05PM Intrexon Announces First Quarter 2018 Financial Results
May 10, 2018 08:00AM Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
May 10, 2018 08:00AM Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
May 3, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
May 3, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent Highlights
May 3, 2018 08:00AM Intrexon to Announce First Quarter 2018 Financial Results on May 10th
Apr 18, 2018 08:29AM Fibrocell Announces Review of Strategic Alternatives
Apr 18, 2018 08:01AM Fibrocell Science (FCSC) to Review Strategic Alternatives
Apr 18, 2018 08:00AM Fibrocell Announces Review of Strategic Alternatives
Apr 18, 2018 08:00AM Fibrocell Announces Review of Strategic Alternatives
Apr 10, 2018 08:00AM Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
Apr 10, 2018 08:00AM Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
Mar 29, 2018 09:28AM Intrexon (XON) Subsidiary ActoBio Therapeutics Granted FDA Approval to Commence Phase Ib/IIa Trial with AG019 for Treatment of Early Onset Type 1 Diabetes
Mar 29, 2018 09:26AM ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes
Mar 19, 2018 08:00AM Fibrocell Reports 2017 Financial Results and Recent Highlights
Mar 19, 2018 08:00AM Fibrocell Reports 2017 Financial Results and Recent Highlights
Mar 12, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
Mar 12, 2018 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent Highlights
Mar 6, 2018 08:00AM Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Mar 1, 2018 04:05PM Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results
Feb 22, 2018 08:00AM Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st
Feb 6, 2018 08:00AM Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
Feb 6, 2018 08:00AM Fibrocell to Present at 20th Annual BIO CEO & Investor Conference
Feb 5, 2018 08:02AM Fibrocell Science (FCSC) Announces Submission of IND for FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
Feb 5, 2018 08:00AM Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Feb 5, 2018 08:00AM Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma
Jan 30, 2018 08:04AM Fibrocell Science (FCSC) Reports FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of RDEB
Jan 30, 2018 08:00AM Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Jan 30, 2018 08:00AM Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Jan 24, 2018 08:00AM Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 
Jan 24, 2018 08:00AM Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 
Jan 4, 2018 08:35AM Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8
Jan 4, 2018 08:30AM Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 2, 2018 08:00AM Intrexon Corporation Annual CEO Letter
Nov 27, 2017 08:00AM Intrexon Announces Key Management Appointments
Nov 13, 2017 08:00AM Fibrocell Reports Third Quarter 2017 Financial Results and Recent Highlights
Nov 10, 2017 08:00AM Intrexon to Present at the Stifel 2017 Healthcare Conference
Nov 9, 2017 04:05PM Intrexon Announces Third Quarter 2017 Financial Results
Nov 6, 2017 08:00AM Fibrocell to Host Conference Call and Webcast on Monday, November 13, 2017 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights
Nov 1, 2017 08:00AM Intrexon to Announce Third Quarter 2017 Financial Results on November 9th
Oct 23, 2017 08:00AM Intrexon and Arch Pharmalabs Collaborate on Fermentative Production of an API to Replace Existing Process Sourced from Animals
Oct 19, 2017 08:00AM Intrexon CEO to Participate in World Food Prize Leadership Panel on Global Hunger
Oct 16, 2017 04:28PM Intrexon (XON) Enters into $100M Preferred Stock Equity Facility
Oct 16, 2017 04:13PM Intrexon Corporation Enters into $100 Million Preferred Stock Equity Facility
Oct 16, 2017 08:00AM Intrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution
View More Recent Stories View Older Stories